Lupus & antiphospholipid syndrome
Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study
Authors' conclusion
PCSK9 inhibitor significantly reduced the risk of SLE but increased the risk of asthma and CD. In contrast, HMGCR inhibitor may be a risk factor for RA, asthma, and CD.
Study context
- Population
- Published genome-wide association studies statistics
- Comparison
- Genetically proxied PCSK9 inhibition vs HMGCR inhibition, on autoimmune disease risk
- Outcome
- Risk of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), myasthenia gravis, multiple sclerosis, asthma, Crohn's disease, ulcerative colitis and type 1 diabetes
Methodological detailsgenetic proxies from published GWAS statistics, HMGCR inhibitor (statin target) as comparator, coronary heart disease as positive control
- Genetic proxies from published GWAS statistics
- HMGCR inhibitor (statin target) as comparator
- Coronary heart disease as positive control
Main finding
As reported in the abstract
Risk of autoimmune diseases
Estimate (95% CI)P value
PCSK9 inhibitor
OR (SLE) 0.47(0.30–0.76)
P = 1.74 × 10-3PCSK9 inhibitor
OR (asthma) 1.15(1.03–1.29)
P = 1.68 × 10-2PCSK9 inhibitor
OR (Crohn's disease) 1.38(1.05–1.83)
P = 2.28 × 10-2HMGCR inhibitor
OR (RA) 1.58(1.19–2.11)
P = 1.67 × 10-3HMGCR inhibitor
OR (asthma) 1.21(1.04–1.40)
P = 1.17 × 10-2HMGCR inhibitor
OR (Crohn's disease) 1.60(1.08–2.39)
P = 2.04 × 10-2Original publication
Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. Arthritis Res Ther. Published 14 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →